Polymyxins: older antibiotics for a new threat.
Polymyxin B and colistin have demonstrated reasonable success in infections due to multidrug-resistant A. baumannii and P. aeruginosa. Polymyxins are only recommended for highly selected cases of serious infections caused by gram-negative bacilli resistant to currently available antibiotics to avoid their potential toxicity. Pharmacodynamic studies are still needed to determine appropriate dosage regimens that will optimize effectiveness and minimize toxicity.
Center for Anti-Infective Research and Development, Hartford Hospital, USA.
Su Young
SY
Lee
Joseph L
JL
Kuti
David P
DP
Nicolau
D000151:Acinetobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D040981:Acinetobacter baumannii / Q000187:drug effects*; D024901:Drug Resistance, Multiple, Bacterial; D006801:Humans; D011113:Polymyxins / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D013997:Time Factors
D011113:Polymyxins